Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Non-cirrhotic MASH with Fibrosis

Cotadutide, a peptide co-agonist at the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors has demonstrated robust improvements in body weight, glycemia, and hepatic fat fraction (HFF) in patients living with obesity and type 2 diabetes mellitus.

Source: Clinical Gastroenterology and Hepatology - May 8, 2024 Category: Gastroenterology Authors: Sudha S. Shankar, Samuel J. Daniels, Darren Robertson, Janeli Sarv, Jos é Sánchez, Debra Carter, Lutz Jermutus, Benjamin Challis, Arun J. Sanyal Source Type: research